Predict your next investment

Corporation
HEALTHCARE | Drug Development
allergan.com

See what CB Insights has to offer

Investments

3

Portfolio Exits

3

Partners & Customers

10

Service Providers

2

About Allergan

Allergan is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.On June 25, 2019, Allergan was acquired by AbbVie at a valuation of $63000M.

Allergan Headquarter Location

Clonshaugh Business and Technology Park Coolock

Dublin, D17 E400,

Ireland

862-261-7000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Allergan

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Allergan in 6 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

E

Eye Health

711 items

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

P

Psychedelics

231 items

L

Life Science & Medical 3D Printing

411 items

Latest Allergan News

Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M

Oct 15, 2021

Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M October 14, 2021 at 3:46 pm News Brief Immusoft CEO Sean Ainsworth. (Immusoft Photo) Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than $900 million. Immusoft’s technology involves engineering a patient’s B cells to mass produce therapeutic proteins. These immune cells are good at pumping out large amounts of proteins, such as an enzyme missing in a particular condition. “This advances our leadership position in B cells as biofactories for therapeutic protein delivery,” said Immusoft CEO Sean Ainsworth in a statement . The new partnership will focus on delivering protein therapeutics across the blood-brain barrier to treat rare neurometabolic conditions. Under the agreement, Takeda has options to exclusively license programs at the preclinical stage and will take products to the clinic and through commercialization. Immusoft will receive research funding support and an undisclosed upfront payment, with total value of option fees and milestone payments of potentially more than $900 million. Immusoft’s most advanced therapeutic program is designed to treat a rare enzyme deficiency disorder, Hurler syndrome. The company aims to file an investigational new drug application for the condition with the U.S. Food and Drug Administration by the end of the year, according to its website , a key step toward a clinical trial. Ainsworth, a veteran biotech exec, has led the company since 2018 when he replaced Matthew Scholz , who founded the company in 2009 and is now CEO of Oisín Biotechnologies . Ainsworth previously founded gene therapy company RetroSense Therapeutics, which sold to Allergan in 2016 in a deal worth up to $555 million. Immusoft closed a $33 million Series B round last year, noted FierceBiotech . Message from the Underwriter

Allergan Investments

3 Investments

Allergan has made 3 investments. Their latest investment was in Stemson Therapeutics as part of their Seed VC on September 9, 2020.

CBI Logo

Allergan Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/16/2020

Seed VC

Stemson Therapeutics

$7.5M

Yes

2

1/10/2017

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

10/14/2010

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/16/2020

1/10/2017

10/14/2010

Round

Seed VC

Series A - II

Series C

Company

Stemson Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$7.5M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

Allergan Portfolio Exits

3 Portfolio Exits

Allergan has 3 portfolio exits. Their latest portfolio exit was Anda on August 02, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/2/2016

Divestiture

$991

4

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/2/2016

00/00/0000

00/00/0000

Exit

Divestiture

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

10

10

Allergan Acquisitions

37 Acquisitions

Allergan acquired 37 companies. Their latest acquisition was Luminera - Dermal Filler Business on October 07, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/7/2020

Acquired Unit

1

3/26/2019

Private Equity

Acquired

1

9/14/2018

Series C

$991

$38.04M

Acquired

1

2/7/2018

Grant - II

Subscribe to see more

$991

$99M

Subscribe to see more

10

12/13/2017

PIPE

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/7/2020

3/26/2019

9/14/2018

2/7/2018

12/13/2017

Investment Stage

Private Equity

Series C

Grant - II

PIPE

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Total Funding

$38.04M

$99M

$99M

Note

Acquired Unit

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Allergan Partners & Customers

10 Partners and customers

Allergan has 10 strategic partners and customers. Allergan recently partnered with Sosei Heptares on January 1, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

1/5/2021

Licensor

Sosei Heptares

Japan

Sosei Heptares To Regain Worldwide Rights To Muscarinic Agonist Programs

We have established partnerships with some of the world 's leading pharmaceutical companies , including AbbVie , AstraZeneca , Biohaven , Genentech , GSK , Novartis , Pfizer and Takeda and additionally with multiple emerging technology companies .

3

6/18/2020

Licensor

Assembly Biosciences

United States

AbbVie nixes microbiome GI program collaboration with Assembly Biosciences

Assembly Biosciences announces that it has regained global rights to all microbiome gastrointestinal programs out-licensed to AbbVie unit Allergan in January 2017 .

1

5/8/2020

Partner

JD Health

China

1

3/4/2020

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

3/3/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

1/5/2021

6/18/2020

5/8/2020

3/4/2020

3/3/2020

Type

Licensor

Licensor

Partner

Licensor

Partner

Business Partner

Sosei Heptares

Assembly Biosciences

JD Health

Country

Japan

United States

China

Subscribe to see more

Subscribe to see more

News Snippet

Sosei Heptares To Regain Worldwide Rights To Muscarinic Agonist Programs

We have established partnerships with some of the world 's leading pharmaceutical companies , including AbbVie , AstraZeneca , Biohaven , Genentech , GSK , Novartis , Pfizer and Takeda and additionally with multiple emerging technology companies .

AbbVie nixes microbiome GI program collaboration with Assembly Biosciences

Assembly Biosciences announces that it has regained global rights to all microbiome gastrointestinal programs out-licensed to AbbVie unit Allergan in January 2017 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

Allergan Service Providers

2 Service Providers

Allergan has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

Allergan Team

42 Team Members

Allergan has 42 team members, including current Senior Vice President, Carrie Strom.

Name

Work History

Title

Status

Carrie Strom

Senior Vice President

Current

Bob Rhatigan

Chief Executive Officer, Senior Vice President

Former

Brenton L. Saunders

Chief Executive Officer

Former

David Endicott

President

Former

Julian Gangolli

President

Former

Name

Carrie Strom

Bob Rhatigan

Brenton L. Saunders

David Endicott

Julian Gangolli

Work History

Title

Senior Vice President

Chief Executive Officer, Senior Vice President

Chief Executive Officer

President

President

Status

Current

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.